mission is to address the growing global challenge of antimicrobial resistance by developing precision biologics that target drug-resistant pathogens while minimizing the development of further resistance. The company's proprietary APEXp platform combines synthetic biology, computational protein engineering, and artificial intelligence to discover and optimize engineered phage lytic proteins (enzybiotics). Rather than relying solely on naturally occurring bacteriophage enzymes, Telum designs synthetic lytic proteins with enhanced potency, stability, and specificity by identifying and recombining functional protein domains. This approach enables the development of targeted antimicrobial therapies against priority bacterial pathogens.